Charlotte Reiche

Charlotte Reiche is a Research Fellow at Memorial Sloan Kettering Cancer Center within the Sloan Kettering Institute and Department of Medicine, specializing in the Immuno-Oncology Program. Her work focuses on developing RNA-based cancer vaccines to target solid tumors, particularly pancreatic cancer.

Her research centers on cancer immunotherapy and RNA vaccine technology, with emphasis on neoantigen discovery, T cell priming mechanisms, and overcoming immunosuppressive tumor microenvironments. She investigates how RNA vaccines generate durable CD8+ T cell responses against malignancies through innovative delivery systems and adjuvant combinations.

Recent publications demonstrate her leadership in translating RNA vaccine principles into clinical applications. The 2025 Nature study established that neoantigen vaccines induce long-lived T cells in pancreatic cancer, while the 2024 Cancer Cell review synthesized current knowledge on cancer vaccine design, manufacturing challenges, and clinical implementation strategies across tumor types.